LONA

Insider Trades

Name	Value	Action	Price	Current Price
Renninger RobertCHIEF FINANCIAL OFFICER $4.9k906 shares SellMar 4, 2026 $5.37 --
Litton Mark JamesDirector, Officer: PRESIDENT And CEO $28k5.2k shares SellMar 4, 2026 $5.37 --
Church KevinCHIEF SCIENTIFIC OFFICER $7.3k1.4k shares SellMar 4, 2026 $5.37 --
San Martin JavierCHIEF MEDICAL OFFICER $9.2k1.7k shares SellMar 4, 2026 $5.37 --
Worthington MarkGENERAL COUNSEL And CCO $7.1k1.3k shares SellMar 4, 2026 $5.37 --
Renninger RobertChief Financial Officer $2.0k297 shares SellJan 2, 2026 $6.88 --

News

globenewswire.comLeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summitglobenewswire.comJun 4

globenewswire.comLeonaBio to Participate in Upcoming Medical and Industry Meetings in Juneglobenewswire.comMay 27

globenewswire.comLeonaBio Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 7

globenewswire.comLeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B.globenewswire.comMay 7

seekingalpha.comLeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene Transcriptseekingalpha.comApr 29

Trade LONA

About LeonaBio, Inc.

LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.

CEO: Mark J. Litton
IPO Date: Sep 18, 2020

Market Data

Open: $8.32
High: $8.46
Low: $8.03
Volume: 5.3K
Avg Volume: 42.7K
52W High: $11.91
52W Low: $4.25

Valuation

Market Cap: $32M
Enterprise Value: $120k
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-46M
Revenue: $0
Net Income: $-106M
Cash: $69M
Debt: $803k

Events

EarningsAug 6

EPS est. -1.11933